Novartis Healthcare Gets CDSCO Panel Nod To study Anti-cancer Drug Asciminib Dr. Divya Colin16 May 2025 5:45 PM ISTNew Delhi: Novartis Healthcare has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis Healthcare Gets CDSCO Panel Nod To study Anti-cancer Drug Asciminib Dr. Divya Colin6 April 2025 3:30 AM ISTNew Delhi: Pharmaceutical major Novartis Healthcare has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Novartis Healthcare Gets CDSCO Panel Nod to Study Asciminib Filmcoated Tablets Dr. Divya Colin28 July 2024 6:00 PM ISTNew Delhi: Suggesting to add more government sites, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization...
CDSCO Panel Approves AstraZeneca's Proposal for Protocol Amendment of anti-cancer drug Asciminib Dr. Divya Colin2 Jan 2024 5:30 AM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis gets CDSCO panel nod to study anticancer drug Asciminib Dr. Divya Colin29 May 2023 9:37 PM ISTNew Delhi: In line with the justification provided by the drug major Novartis, the Subject Expert Committee (SEC) functional under the Central Drug...
Novartis gets CDSCO panel go ahead for Asciminib Phase 3 trial Roshni Dhar21 Nov 2021 5:18 PM ISTIn a significant development, major drug-maker Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs...
Health Bulletin 20/November/2021 Roshni Dhar20 Nov 2021 4:17 PM ISTHere are Top Health stories of the dayDuty of Medical Council to ensure that doctors do not indulge in offences: Madras HCHolding that it is the duty...
Novartis gets CDSCO panel nod to conduct phase 3 study of anti-cancer drug Asciminib Medical Dialogues Team18 Nov 2021 4:25 PM ISTNew Delhi: In a significant development, major drug-maker Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the...
Novartis Scemblix gets USFDA nod for chronic myeloid leukemia Ruchika Sharma31 Oct 2021 10:00 AM ISTBasel: Novartis has recently announced that the US Food and Drug Administration (FDA) has approved Scemblix (asciminib) for the treatment of chronic...
Novartis gets USFDA Breakthrough Therapy designations for STAMP inhibitor asciminib to treat chronic myeloid leukemia Ruchika Sharma9 Feb 2021 11:00 AM ISTAsciminib (ABL001) is an investigational treatment specifically targeting the ABL myristoyl pocket (STAMP).
Novartis push to expand cancer arsenal gets trial win against Pfizer Bosulif Ruchika Sharma28 Aug 2020 9:30 AM ISTZurich: Novartis drug candidate asciminib notched a trial win against Pfizer's Bosulif, the Swiss drugmaker said on Wednesday, as it pushes to expand...
